A prior study showed that Bifidobacterium can ameliorate hepatic steatosis and inflammation in HFD-induced chronic liver disease mice by suppressing the NF-κB signaling pathway—this effect is mediated by reduced endotoxin levels and inactivation of macrophages [36]. This evidence concerns the gene NFKB1 and fatty liver disease.